5-Amino-1MQ is the compound I get asked about most by people who have already run a GLP-1 and want something that works on the other side of the equation. Semaglutide and tirzepatide shut down appetite. This one leaves appetite alone and goes after the fat cell itself, through an enzyme called NNMT. In the animal work, obese mice on it lost fat mass while eating the same amount of food, which is a different kind of result from anything an appetite drug produces.
It gets lumped in with peptides because it sits on the same vendor menus. It is not one. It is a small molecule, and that matters for how it is taken, because it is one of the few compounds in this space that works by mouth.
A lot has happened since I last updated this guide. A 2024 study ran 5-Amino-1MQ itself for 28 days in obese mice and improved fat mass, glucose tolerance, and liver fat at the same time. Another 2024 paper showed 22-month-old mice on it gained about 40% grip strength without exercising at all. And in June 2026, Trends in Pharmacological Sciences published a review on getting NNMT inhibitors into human trials, which tells you where the field thinks this is headed. The human data is still thin, and I will be specific about that below, but the direction of travel is not subtle.
If you want to skip to sourcing, I point readers to Paramount Peptides, which sells it as pre-dosed 30mg tablets with a posted Janoshik COA, and code BRAINFLOW takes 10% off. Tablets fix the two problems that ruin most people’s first run with this compound, and both get explained below.
Key Takeaways
- 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide, and it is orally active
- Blocking NNMT spares nicotinamide for NAD+ and preserves methyl groups, which pushes fat cells from storing energy toward burning it
- The animal data is consistent across a decade: less fat mass with no drop in food intake (2018, 2021, 2024), better glucose tolerance, less liver fat, and about 40% more grip strength in aged mice (2024)
- No human trials are registered as of September 2026. A June 2026 review notes one NNMT-inhibitor trial has started, using a newer molecule
- Dosing is in milligrams (50 to 150 mg a day). The most common failure is dosing in micrograms, and pre-dosed 30mg tablets make that error impossible
What Is 5-Amino-1MQ? (And Why It Is Not a Peptide)
5-Amino-1MQ, short for 5-amino-1-methylquinolinium, is a small synthetic molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that runs hot in the fat tissue of obese animals and people. It came out of Stanley Watowich’s lab at the University of Texas Medical Branch, and it is studied mainly for fat loss, insulin sensitivity, and muscle function.
Peptides are chains of amino acids. This has none. It is built on a quinolinium ring, and the active part weighs in around 159 g/mol, roughly a ninth the size of BPC-157. That size difference is the practical point. Molecules this small survive digestion and get absorbed, which is why it is taken by mouth while nearly everything else on the vendor menu needs a needle.
The peptide label also drags in habits that do not apply. There is nothing to reconstitute, no bacteriostatic water, no insulin-syringe math. You take a measured amount, usually in the morning, and that is the whole procedure.
One more framing point before the mechanism. This is not a GLP-1 and it is not trying to be. Semaglutide and tirzepatide are approved drugs with tens of thousands of trial participants behind them. 5-Amino-1MQ is a research compound going after a different target, and the two approaches barely overlap. That is why it shows up in stacks alongside GLP-1s rather than as a replacement for them.
BrainFlow Recommended Source
Paramount Peptides: 5-Amino-1MQ 30mg Tablets
60 pre-dosed 30mg tablets, 1,800mg per bottle, for $156.00. Code BRAINFLOW takes 10% off (about $140.40), which works out to under 8 cents per milligram against $1.50 to $5 per milligram for the vials most vendors sell. Janoshik-tested with the COA posted, stable at room temperature, and no scale or syringe math. Two tablets is 60mg. Done.
Shop 5-Amino-1MQ Tablets →For laboratory and research use only. Not for human consumption.
How 5-Amino-1MQ Works: The NNMT Mechanism
NNMT stands for nicotinamide N-methyltransferase. Its job is narrow. It takes nicotinamide, a form of vitamin B3, and tags it with a methyl group borrowed from SAM, the cell’s main methyl donor. The output is 1-methylnicotinamide, and the nicotinamide that got tagged is now spent.
That is a bigger deal than it sounds, because nicotinamide is one of the raw materials cells recycle into NAD+, the coenzyme behind energy production and the sirtuins. When NNMT runs hot it drains nicotinamide and burns through the methyl budget at the same time. In fat tissue that shows up as sluggish, storage-mode adipocytes. NNMT is elevated in the fat of obese, insulin-resistant animals and people, and the more of it there is, the worse the metabolic picture tends to look.
The study that put NNMT on the map is a 2014 paper in Nature from Barbara Kahn’s group. Knocking NNMT down in fat and liver protected mice from diet-induced obesity by raising energy expenditure, with no change in how much they ate. That was the proof of concept. 5-Amino-1MQ is the small molecule built to do the same job with a pill instead of gene silencing.
Two levers do most of the work once the enzyme is blocked. The first is NAD+. Spared nicotinamide feeds the salvage pathway that keeps NAD+ topped up, and NAD+ is what powers SIRT1, the sirtuin tied to mitochondrial biogenesis and metabolic efficiency.
The second lever is the methyl budget. NNMT burns SAM, so blocking it leaves more methyl groups available for the reactions that regulate gene expression. In fat cells the combination reads as a shift from storing energy to spending it, which is why the animal studies show smaller adipocytes and higher oxygen consumption rather than a change in appetite.
NNMT is not a villain everywhere, though. In the liver its activity can help with lipid handling, which is why one review called it a bad actor in fat that makes good in liver. That nuance is a big part of why the research focus is on fat-selective inhibition, and it is why I treat this as a cycled tool rather than a daily-forever supplement.
5-Amino-1MQ Benefits: What the Research Shows
The preclinical file on this compound is unusually consistent for something sold on the gray market. The same lab has published on it for a decade, independent groups have replicated the core fat-loss finding, and the 2024 papers extended it into glucose control, liver fat, and aged muscle. Every study below is in animals, and the human section that follows deals with that plainly. First, the record.
Consistent in animals
Fat loss and body composition. The 2018 Biochemical Pharmacology study showed selective NNMT inhibitors reversed diet-induced obesity in mice, shrinking fat mass and adipocyte size while leaving food intake and lean mass alone. Babula and colleagues (2024) then ran 5-Amino-1MQ itself once a day for 28 days and got dose-dependent limits on fat gain plus better glucose tolerance, better insulin sensitivity, and less fat in the liver. The fat-without-appetite result has now held across three separate designs.
Muscle strength in aging. This tier moved up since the last version of this guide. Dimet-Wiley and colleagues (2024) gave 22 to 24 month old mice daily 5-Amino-1MQ for eight weeks. Sedentary treated mice ended up with about 40% more grip strength than sedentary controls. Exercise alone produced a 20% gain. Exercise plus the compound produced about 60%, and the treated runners held their improved endurance through week eight while the untreated runners drifted back to baseline. That builds on the 2019 muscle regeneration work, where NNMT inhibition woke up senescent muscle stem cells in old mice.
Promising, still early
Glucose, insulin, and liver fat. The 2024 Babula study is the strongest signal here, with improved oral glucose tolerance, suppressed hyperinsulinemia, and reduced hepatic steatosis after 28 days. A 2021 review of NNMT in obesity and type 2 diabetes noted no clinical trials had been reported, and that is still true for this molecule. Newer 2025 papers have pushed NNMT inhibition into peripheral artery disease and heart failure models, which says something about how broadly the enzyme is being looked at.
Mechanism, not yet evidence
NAD+, mitochondria, longevity. Sparing nicotinamide plausibly supports the NAD+ salvage pathway, and a 2024 review framed NNMT as an aging target. But preserving NAD+ raw materials in some tissues is not the same thing as an NAD+ booster like NMN, and nobody has measured a healthspan effect in people. This is mechanism that rhymes with the longevity literature, and I would not buy it for this reason alone.
Where the Human Evidence Stands in 2026
Every claim above comes from mice. A ClinicalTrials.gov search in September 2026 returns zero registered studies for 5-Amino-1MQ under its common name, its chemical name, or its drug class. There is no published human safety data and no human weight-loss trial. Anyone quoting human efficacy numbers for this compound is making them up.
The field is moving, though. The June 2026 review in Trends in Pharmacological Sciences by Puleo and colleagues lays out the case for clinical translation and notes that one dedicated clinical trial has now been initiated with an NNMT small-molecule inhibitor. It is a newer molecule, not 5-Amino-1MQ. The same review describes the current generation of inhibitors as orally bioavailable with nanomolar potency inside cells, which is the profile you want before a first-in-human study.
Where that leaves 5-Amino-1MQ is as the first-generation tool compound the newer molecules were built from, with roughly a decade of people using it for fat loss and a consistent anecdotal pattern, but no controlled human data. Metabolic targets that look great in rodents have a long history of fizzling in people, so the mouse record buys it a seat at the table and not a verdict. I run it with that understanding, and with bloodwork, which I get to below.
5-Amino-1MQ Dosage: How Much People Take
Real-world use is years ahead of the research, so the ranges below come from clinic-style protocols, vendor labels, and user logs rather than trials. Read them as what people do, not as a prescription.
The mistake that sinks more first attempts than anything else is a units error, milligrams versus micrograms. Someone reads a microgram figure on a forum, doses a thousandth of the intended amount, feels nothing after a month, and writes the compound off. If a dose you see quoted is a thousand times smaller than everyone else’s, that is a typo you are looking at, not a conservative protocol.
Pre-dosed tablets make that error impossible, which is the first reason I moved my recommendation to them. Paramount’s tablets are 30mg each, so the common ranges map onto whole tablets. Two is 60mg, three is 90mg, five is 150mg. No milligram scale, no eyeballing powder, no conversion.
Splitting the daily amount comes from the pharmacokinetics. Reported preclinical half-life lands somewhere around 3.8 to 6.9 hours, short enough that one morning dose may not hold NNMT inhibition steady across the whole day. So a lot of protocols run half in the morning and half in the early afternoon, and stop there. That same short half-life is why late-day dosing is the usual culprit behind the sleep complaints, and why I tell people nothing after 2 pm.
The ramp people describe is simple. Start at 50 or 60mg, hold for two to four weeks to see how it sits, and only move toward 90 to 150mg if the lower amount is uneventful. Nothing suggests starting high does anything except raise the odds of stomach upset. Cycle length splits two ways. Most run 8 to 12 weeks on with a similar break. Some prefer 20 to 30 day blocks with a one to two week pause on the theory that a rest lets NAD+ metabolism resettle. No trial says which is right, so both are educated guesses, and the liver nuance above is a decent argument for cycling at all.
Tablets, powder, or injection?
Injectable protocols still show up, usually subcutaneous at about 50 mg a day, and they bring the friction of reconstituting with bacteriostatic water and keeping a vial cold. There is not much reason to bother. Part of the early pharmacology suggested injected drug is cleared largely unchanged in the urine, and the compound’s whole appeal is that it is one of the few orally active tools in a market built on injectables. Practitioners who like it tend to run it by mouth.
Between the two oral formats, powder is cheaper up front and worse in every other way. It needs a milligram scale, it is where the mcg error lives, and it degrades with light and heat if handled casually. Tablets cost more per bottle, far less per milligram, and remove the handling problem. If you have a scale and know what you are doing, powder is fine. If you are running this for the first time, tablets.
5-Amino-1MQ Results: What to Expect at 4, 8, and 12 Weeks
Nobody has published a human before-and-after, so any timeline is stitched together from the mouse data and a lot of user logs. Even so, the anecdotal pattern has been stable for years.
Weeks one and two, people mention steadier energy and cleaner focus, which fits the NAD+ story and is also the easiest thing to get from placebo. Appetite mostly does not move, which is the point. By weeks four to six, training feels better and recovery between sessions improves, and this is where the 2024 aged-muscle data makes the reports easier to believe. Body-composition changes get reported around weeks eight to twelve, almost always by people who were already in a deficit and training. Remove the deficit and the training and there is not much left to report.
Measure instead of guessing. Baseline bloodwork before you start, then a recheck at 8 to 12 weeks, turns a feeling into a data point. The panel I use is fasting glucose, fasting insulin, HOMA-IR, HbA1c, a lipid panel, and ALT. That covers the metabolic markers the mouse studies moved and flags liver or glucose trouble early, which is the one place the theoretical concerns would show up first.
Stacking 5-Amino-1MQ: GLP-1s, MOTS-c, and Tesamorelin
The question I get most is some version of “is this a natural Ozempic,” and the answer is no, because the two are not playing the same game. Semaglutide averaged about 15% body-weight loss over 68 weeks in its pivotal trial, tirzepatide passed 20% at the top dose, and they do it by cutting appetite and slowing digestion. 5-Amino-1MQ does not touch appetite. It works on what the fat cell does with the energy it already has.
That difference is why 5-Amino-1MQ shows up as a stack partner rather than a standalone. The most common pairing is with a GLP-1, on the logic that the drug handles intake while the compound works the fat cell, with the 2024 muscle data offering some hope on the lean-mass losses GLP-1 users complain about. It is a reasonable theory with zero combination trials behind it, and layering a research compound onto a prescription drug is the kind of thing that needs a clinician who knows about both.
Beyond GLP-1s, people pair it with MOTS-c for the shared mitochondrial angle, with tesamorelin when visceral fat is the target, and with NMN on the theory that one spares NAD+ precursors while the other supplies them. Creatine, berberine, and L-carnitine round out the supplement-tier additions. None of these combinations have been studied together, and every extra experimental agent makes your own results harder to read.
Whatever the stack, the deficit, the protein, the training, and the sleep still do most of the work. In the mouse data, NNMT inhibition plus a reduced-calorie diet beat the diet alone, which is the right way to think about this compound. It improves the return on effort you are already putting in.
5-Amino-1MQ Side Effects and Safety
Vendor pages love the phrase “no known side effects.” What that means is “barely studied in people.” In the mouse studies, researchers saw no obvious adverse effects at the doses tested and no cell toxicity in lab assays, and the 2024 studies ran daily dosing for four and eight weeks without flagging problems. Those are still short animal studies.
From users, the picture is mild. The most common complaint is trouble sleeping when it is taken late, which morning dosing fixes. Some report stomach upset at the top of the range, usually settled by taking it with food. Appetite reports go both directions. Nothing in the user record looks like a pattern of serious harm, and nothing in it is well characterized either.
The theoretical concerns deserve a paragraph because the data to rule them out does not exist. NNMT sits where methylation and NAD+ metabolism cross, so long-term manipulation could shift things nobody is measuring. Its protective role in the liver means permanent blanket inhibition is not obviously harmless, which is one more argument for cycles and bloodwork. Drug interactions are unstudied. Pregnancy or breastfeeding, liver or kidney disease, a cancer history, or medications that touch methylation or glucose handling all move this from “run it carefully” to “talk to a physician first.”
Is 5-Amino-1MQ Legal in 2026?
“You can buy it online” and “it is approved” are not the same sentence. The FDA has not approved 5-Amino-1MQ for weight loss or anything else, and it is not a recognized dietary supplement ingredient, so it cannot be lawfully sold as a supplement. That is why every vendor labels it for research use only. The FDA has repeatedly treated that label as meaningless when a product is plainly marketed and dosed for people, so the label protects the seller more than it clarifies anything for you.
The compounding angle is weaker than clinic marketing suggests. 5-Amino-1MQ is not on the FDA’s 503A bulk drug substances list, and it was not among the seven compounds the FDA’s Pharmacy Compounding Advisory Committee reviewed in July 2026. That meeting recommended BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for compounding and rejected DSIP.
5-Amino-1MQ was not on the agenda and has no scheduled review, so a clinic offering it as “compounded” is not standing on the ground that phrase implies. FDA guidance from early 2025 tightened compounding of substances without established monographs, which points the same direction.
For tested athletes the answer is simpler. Anything without approval from a health authority falls under WADA’s S0 catch-all for non-approved substances, so it is banned at all times in tested sport. Outside the US, treatment varies by country and shipments do get held, so check your own rules before ordering.
Where to Buy 5-Amino-1MQ: Tested Tablets vs Powder
This is where a real result and a wasted two months get decided, because the compound is sold as a research chemical in a market full of underdosed and mislabeled product. Three things tell you whether you are getting what you paid for. A certificate of analysis from a named lab that matches the lot you receive, a stated purity for the active ingredient, and a format that protects the material between the lab and your kitchen counter.
I point readers to Paramount Peptides, which sells 5-Amino-1MQ as compressed 30mg tablets, 60 to a bottle, with a Janoshik COA posted for the lot and a stated purity of 98% or higher for the active ingredient. The bottle is $156.00, and code BRAINFLOW takes 10% off, to about $140.40. Orders ship the next business day from the US, and the price steps down again at 5 and 10 bottles.
The per-milligram math is the second reason I moved to tablets. A bottle holds 1,800mg, which comes out under 8 cents a milligram with the code. Vials of this compound have typically sold at somewhere between $1.50 and $5 per milligram depending on size. At 60mg a day, the tablets run under $5 a day and a bottle lasts a month. The same 60mg from vials runs anywhere from about $90 a day to several hundred, which is a big part of why so many people quietly ran this compound at a fraction of the discussed dose for years and concluded it did nothing.
If the priority is the lowest upfront spend and you already own a milligram scale, Amino Club sells lab-tested lyophilized powder, and code BRAINFLOW takes 20% off there. You trade the pre-dosed convenience and the room-temperature stability for a cheaper way in.
Storage is the last piece. Tablets keep at room temperature in the sealed bottle, dry and out of light, which is the whole advantage of a compressed format. Powder is fussier. Like many research compounds it degrades with UV and ambient light, so lyophilized material belongs cold, dark, and sealed from the day it arrives, and anything reconstituted for injection moves to the fridge with a much shorter window. A good vial handled badly still ends up weak.
Pre-Dosed · Janoshik Tested
The Format That Makes the Real Dose Affordable
At 60mg a day, a bottle of Paramount’s 30mg tablets lasts a month and costs under $5 a day with the code. The same 60mg from vials runs $90 a day and up, which is why so many people underdosed this compound for years without knowing it.
$156.00 for 60 tablets, and code BRAINFLOW takes 10% off. COA posted, ships next business day from the US, volume pricing at 5 and 10 bottles.
Get 5-Amino-1MQ Tablets →For laboratory and research use only. Not for human consumption.
My Take
BrainFlow Verdict
5-Amino-1MQ is the most interesting metabolic compound in the research space right now, and I say that as someone who spends most of his time on peptides. The NNMT mechanism is clean, the animal record is a decade deep and points one direction, and the 2024 papers added the two things I wanted to see, a 28-day study of the compound itself with glucose and liver benefits, and a strength effect in old animals that looked like exercise in a pill. Then a June 2026 review in a serious journal said the field is heading for human trials.
What it does not have is a single human study, and I would rather tell you that once, clearly, than pretend the forum reports settle it. If you run it, run it properly. Milligrams, not micrograms. Morning, not night. A deficit and a training block around it. Pre-dosed tablets so the amount in your hand is the amount on the label. And bloodwork before and after, so at the end of 12 weeks you know whether it did anything instead of hoping it did.
5-Amino-1MQ FAQ
Is 5-Amino-1MQ a peptide?
No. It is a small synthetic molecule with no amino-acid chain, an NNMT inhibitor built on a quinolinium ring. It gets sold and discussed alongside peptides, which is where the confusion comes from, and being a small molecule is why it works orally.
Does 5-Amino-1MQ work for weight loss?
In obese mice, yes, across studies from 2018, 2021, and 2024. Fat mass dropped without any cut in food intake, and the 2024 study added better glucose tolerance and less liver fat. In humans there are no published trials, so the effect is not established in people. The user pattern is fat loss during a deficit and training block, not on its own.
How long does 5-Amino-1MQ take to work?
People report energy and focus changes in the first two weeks, better training and recovery around weeks four to six, and body-composition changes around weeks eight to twelve. Every one of those is anecdotal, which is why baseline and follow-up bloodwork is the only way to know what it did for you.
What is the typical 5-Amino-1MQ dosage?
Discussed oral ranges sit at 50 to 150 mg a day, cycled for 8 to 12 weeks, often split between morning and early afternoon. With 30mg tablets that is two to five tablets a day. The units are milligrams. If you see a microgram figure, it is an error, and dosing to it is the single most common reason people report no effect.
Can I take 5-Amino-1MQ with semaglutide or tirzepatide?
It is the most common stack, on the logic that the GLP-1 handles appetite while 5-Amino-1MQ works on the fat cell and may help with the muscle loss GLP-1 users report. No combination study exists. Since one of the two is a prescription drug, this is a conversation for the prescriber, not a forum.
Does 5-Amino-1MQ build muscle?
Not the way a secretagogue or anabolic does. In aged mice it reactivated senescent muscle stem cells and, in the 2024 study, produced about 40% more grip strength in sedentary animals and about 60% when combined with treadmill running. That is a muscle-quality and recovery signal in old animals, not a mass-building effect in a young lifter.
5-Amino-1MQ vs NMN: which is better for NAD+?
They do different jobs. NMN supplies a precursor to NAD+. 5-Amino-1MQ stops NNMT from wasting nicotinamide, so more of the existing raw material gets recycled. NMN has human trials showing it raises NAD+ levels. 5-Amino-1MQ does not. If NAD+ is the goal, NMN is the evidence-backed choice, and some people run both on the theory that they are complementary.
What are the side effects of 5-Amino-1MQ?
Mild, based on user reports. Sleep disruption from late dosing and stomach upset at higher doses are the two that come up. No human safety study exists, and the theoretical concerns around methylation and long-term liver effects are the reason to cycle it and check bloodwork rather than run it indefinitely.
Is 5-Amino-1MQ legal?
It is sold as a research compound, not a lawful supplement ingredient. It is not FDA-approved, not on the 503A compounding list, was not part of the July 2026 FDA advisory review, and is banned in tested sport under WADA’s S0 category. Personal possession in the US is a gray area rather than a crime.
Where can I buy 5-Amino-1MQ?
I point readers to Paramount Peptides for 30mg tablets, 60 to a bottle, with a Janoshik COA posted. Code BRAINFLOW takes 10% off the $156.00 price. Tablets remove the dosing error and the storage problem in one move. Amino Club is the lower-cost powder option if you have a milligram scale, with code BRAINFLOW for 20% off.
This article is for educational and research purposes only and is not medical advice. 5-Amino-1MQ is not FDA-approved to diagnose, treat, cure, or prevent any disease and is sold for research use only. Consult a qualified healthcare provider before starting any compound or protocol.
This article contains affiliate links to Paramount Peptides and Amino Club. BrainFlow may earn a commission on qualifying purchases at no additional cost to the reader. We only recommend sources we trust.
Last updated September 2026.
1 Comment